Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Siccardi

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|July 12, 2018
Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept studyR K R Rajoli, A T Podany, D M Moss, et al.
Gastroenterology Clinics of North America|September 1, 1987
Gastric histomorphology and secretory biochemistry after biliopancreatic diversionG F Adami, E Gianetta, S Sulfaro, et al.
Clinical Pharmacology and Therapeutics|July 19, 2012
Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation modelM Siccardi, L Almond, A Schipani, et al.
The Journal of Antimicrobial Chemotherapy|August 20, 2015
Prevalence and type of drug-drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, UgandaK Seden, C Merry, R Hewson, et al.
Clinical Pharmacology and Therapeutics|February 11, 2017
The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or NevirapineM Neary, M Lamorde, A Olagunju, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|June 14, 2021
Methodological needs in the quality and safety characterisation of nanotechnology-based health products: Priorities for method development and standardisationB Halamoda-Kenzaoui, R J Vandebriel, A Howarth, et al.
The Journal of Antimicrobial Chemotherapy|July 16, 2015
Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study)S Bonora, S Rusconi, A Calcagno, et al.
European Journal of Haematology|February 19, 2000
Alpha-interferon as induction and maintenance therapy in hairy cell leukemia: a long-term follow-up analysisE E Damasio, M Clavio, B Masoudi, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|March 7, 2018
Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challengesS Swindells, M Siccardi, S E Barrett, et al.
The Journal of Antimicrobial Chemotherapy|February 2, 2008
The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferonD Aguilar Marucco, D Gonzalez de Requena, S Bonora, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|July 12, 2018
Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept studyR K R Rajoli, A T Podany, D M Moss, et al.
Gastroenterology Clinics of North America|September 1, 1987
Gastric histomorphology and secretory biochemistry after biliopancreatic diversionG F Adami, E Gianetta, S Sulfaro, et al.
Clinical Pharmacology and Therapeutics|July 19, 2012
Pharmacokinetic and pharmacodynamic analysis of efavirenz dose reduction using an in vitro-in vivo extrapolation modelM Siccardi, L Almond, A Schipani, et al.
The Journal of Antimicrobial Chemotherapy|August 20, 2015
Prevalence and type of drug-drug interactions involving ART in patients attending a specialist HIV outpatient clinic in Kampala, UgandaK Seden, C Merry, R Hewson, et al.
Clinical Pharmacology and Therapeutics|February 11, 2017
The Effect of Gene Variants on Levonorgestrel Pharmacokinetics When Combined With Antiretroviral Therapy Containing Efavirenz or NevirapineM Neary, M Lamorde, A Olagunju, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|June 14, 2021
Methodological needs in the quality and safety characterisation of nanotechnology-based health products: Priorities for method development and standardisationB Halamoda-Kenzaoui, R J Vandebriel, A Howarth, et al.
The Journal of Antimicrobial Chemotherapy|July 16, 2015
Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study)S Bonora, S Rusconi, A Calcagno, et al.
European Journal of Haematology|February 19, 2000
Alpha-interferon as induction and maintenance therapy in hairy cell leukemia: a long-term follow-up analysisE E Damasio, M Clavio, B Masoudi, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|March 7, 2018
Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challengesS Swindells, M Siccardi, S E Barrett, et al.
The Journal of Antimicrobial Chemotherapy|February 2, 2008
The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferonD Aguilar Marucco, D Gonzalez de Requena, S Bonora, et al.
Pageof 3